{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-109479","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.637840+00:00","generated_at":"2026-05-16T20:42:01.864999+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TherapeuticsMD posts Q3 net income of $50K vs year-ago loss; license revenue up 43%","bullets":["Net income from continuing operations was $50K ($0.00 per share) vs net loss of $567K ($0.05) in Q3 2024.","License revenue from Mayne Agreement rose 43% to $784K from $547K year-over-year.","Total operating expenses decreased 2.1% to $1,646K, roughly flat from prior year.","Company evaluating strategic alternatives including M&A, sale of assets; no timetable set.","Cash and cash equivalents stood at $7.1 million as of September 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-109479","json":"https://secwatch.observer/filing/0001213900-25-109479.json","markdown":"https://secwatch.observer/filing/0001213900-25-109479.md","text":"https://secwatch.observer/filing/0001213900-25-109479.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000121390025109479/0001213900-25-109479-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000121390025109479/ea0265416-8k_therape.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:42:01.864999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}